FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294204315> ?p ?o ?g. }

• W4294204315 abstract "Abstract Background Pre-eclampsia is a complex pregnancy disorder, characterised by new or worsening hypertension associated with multi-organ dysfunction. Adverse outcomes include eclampsia, liver rupture, stroke, pulmonary oedema, and acute kidney injury in the mother, and stillbirth, foetal growth restriction, and iatrogenic preterm delivery for the foetus. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing for suspected preterm pre-eclampsia has been incorporated into national guidance. The role of repeat PlGF-based testing and its effect on maternal and perinatal adverse outcomes have yet to be evaluated. Methods The PARROT-2 trial is a multi-centre randomised controlled trial of repeat revealed PlGF-based testing compared to repeat concealed testing, in women presenting with suspected pre-eclampsia between 22 +0 and 35 +6 weeks’ gestation. The primary objective is to establish whether repeat PlGF-based testing decreases a composite of perinatal severe adverse outcomes (stillbirth, early neonatal death, or neonatal unit admission). All women prior to enrolment in the trial will have an initial revealed PlGF-based test. Repeat PlGF-based tests will be performed weekly or two-weekly, depending on the initial PlGF-based test result, with results randomised to revealed or concealed. Discussion National guidance recommends that all women presenting with suspected preterm pre-eclampsia should have a single PlGF-based test when disease is first suspected, to help rule out pre-eclampsia. Clinical and cost-effectiveness of repeat PlGF-based testing has yet to be investigated. This trial aims to address whether repeat PlGF-based testing reduces severe maternal and perinatal adverse outcomes and whether repeat testing is cost-effective. Trial registration ISRCTN 85912420 . Registered on 25 November 2019" @default.
• W4294204315 created "2022-09-02" @default.
• W4294204315 creator A5019981779 @default.
• W4294204315 creator A5030298769 @default.
• W4294204315 creator A5032448943 @default.
• W4294204315 creator A5032740727 @default.
• W4294204315 creator A5038755860 @default.
• W4294204315 creator A5039524951 @default.
• W4294204315 creator A5044391206 @default.
• W4294204315 creator A5046717506 @default.
• W4294204315 creator A5055287528 @default.
• W4294204315 creator A5058778952 @default.
• W4294204315 creator A5059386114 @default.
• W4294204315 creator A5064959070 @default.
• W4294204315 date "2022-09-02" @default.
• W4294204315 modified "2023-10-18" @default.
• W4294204315 title "Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2)" @default.
• W4294204315 cites W150568556 @default.
• W4294204315 cites W1973680815 @default.
• W4294204315 cites W1974305506 @default.
• W4294204315 cites W2006245385 @default.
• W4294204315 cites W2126728600 @default.
• W4294204315 cites W2139649412 @default.
• W4294204315 cites W2145917688 @default.
• W4294204315 cites W2233974801 @default.
• W4294204315 cites W2247856738 @default.
• W4294204315 cites W2414135647 @default.
• W4294204315 cites W2557169092 @default.
• W4294204315 cites W2589164015 @default.
• W4294204315 cites W2754928405 @default.
• W4294204315 cites W2790948098 @default.
• W4294204315 cites W2911226809 @default.
• W4294204315 cites W2930104874 @default.
• W4294204315 cites W2938408816 @default.
• W4294204315 cites W2988264143 @default.
• W4294204315 cites W3004881066 @default.
• W4294204315 cites W3045361571 @default.
• W4294204315 cites W3149074076 @default.
• W4294204315 cites W4211051919 @default.
• W4294204315 cites W4251118184 @default.
• W4294204315 cites W4382916220 @default.
• W4294204315 doi "https://doi.org/10.1186/s13063-022-06652-8" @default.
• W4294204315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36056408" @default.
• W4294204315 hasPublicationYear "2022" @default.
• W4294204315 type Work @default.
• W4294204315 citedByCount "4" @default.
• W4294204315 countsByYear W42942043152023 @default.
• W4294204315 crossrefType "journal-article" @default.
• W4294204315 hasAuthorship W4294204315A5019981779 @default.
• W4294204315 hasAuthorship W4294204315A5030298769 @default.
• W4294204315 hasAuthorship W4294204315A5032448943 @default.
• W4294204315 hasAuthorship W4294204315A5032740727 @default.
• W4294204315 hasAuthorship W4294204315A5038755860 @default.
• W4294204315 hasAuthorship W4294204315A5039524951 @default.
• W4294204315 hasAuthorship W4294204315A5044391206 @default.
• W4294204315 hasAuthorship W4294204315A5046717506 @default.
• W4294204315 hasAuthorship W4294204315A5055287528 @default.
• W4294204315 hasAuthorship W4294204315A5058778952 @default.
• W4294204315 hasAuthorship W4294204315A5059386114 @default.
• W4294204315 hasAuthorship W4294204315A5064959070 @default.
• W4294204315 hasBestOaLocation W42942043151 @default.
• W4294204315 hasConcept C126322002 @default.
• W4294204315 hasConcept C131872663 @default.
• W4294204315 hasConcept C167734588 @default.
• W4294204315 hasConcept C168563851 @default.
• W4294204315 hasConcept C197934379 @default.
• W4294204315 hasConcept C2776871010 @default.
• W4294204315 hasConcept C2777025900 @default.
• W4294204315 hasConcept C2779234561 @default.
• W4294204315 hasConcept C2781276381 @default.
• W4294204315 hasConcept C54355233 @default.
• W4294204315 hasConcept C71924100 @default.
• W4294204315 hasConcept C86803240 @default.
• W4294204315 hasConceptScore W4294204315C126322002 @default.
• W4294204315 hasConceptScore W4294204315C131872663 @default.
• W4294204315 hasConceptScore W4294204315C167734588 @default.
• W4294204315 hasConceptScore W4294204315C168563851 @default.
• W4294204315 hasConceptScore W4294204315C197934379 @default.
• W4294204315 hasConceptScore W4294204315C2776871010 @default.
• W4294204315 hasConceptScore W4294204315C2777025900 @default.
• W4294204315 hasConceptScore W4294204315C2779234561 @default.
• W4294204315 hasConceptScore W4294204315C2781276381 @default.
• W4294204315 hasConceptScore W4294204315C54355233 @default.
• W4294204315 hasConceptScore W4294204315C71924100 @default.
• W4294204315 hasConceptScore W4294204315C86803240 @default.
• W4294204315 hasFunder F4320325703 @default.
• W4294204315 hasIssue "1" @default.
• W4294204315 hasLocation W42942043151 @default.
• W4294204315 hasLocation W42942043152 @default.
• W4294204315 hasLocation W42942043153 @default.
• W4294204315 hasLocation W42942043154 @default.
• W4294204315 hasLocation W42942043155 @default.
• W4294204315 hasLocation W42942043156 @default.
• W4294204315 hasLocation W42942043157 @default.
• W4294204315 hasOpenAccess W4294204315 @default.
• W4294204315 hasPrimaryLocation W42942043151 @default.
• W4294204315 hasRelatedWork W1993079004 @default.
• W4294204315 hasRelatedWork W2001631557 @default.
• W4294204315 hasRelatedWork W2043432888 @default.
• W4294204315 hasRelatedWork W2060432109 @default.

• next